Across
- 2. Receptor predominantly more responsible for angiogenesis(4)
- 5. Inlyta is a ______ coated tablet(4)
- 6. The author of the Outcome study of Axitinib Vs Sorafenib to access quality of life(5)
- 8. Category 1 recommendation guideline for Inlyta in 2nd line mRCC treatment(4)
- 10. Most common side effect of Inlyta(12)
- 11. Median PFS of Inlyta in Asian patients (In numeric)(3)
- 12. Maximum dose of Inlyta in mg(3)
- 13. % Bioavailability of Inlyta (In numeric)(2)
Down
- 1. Shelf life of Inlyta in Years(5)
- 3. Recommended starting dose of Inlyta in mg BID(5)
- 4. % ORR of INLYTA in AXIS 1032 trial (In words)(7)
- 5. Metabolites of Axitininb are primarily excreted in(5)
- 7. Axitinib is primarily metabolised by organ(5)
- 9. Primary enzyme responsile to metabolise Axitinib(8)
